Lease, Finance or Revenue-Share: Choosing an Equipment Acquisition Model (2026)
Four acquisition models dominate aesthetic equipment: outright purchase, equipment finance (hire purchase), operating lease, and revenue-share placement. Purchase maximises long-run return and control but concentrates capital and risk. Finance spreads payments while building ownership. An operating lease minimises upfront cash and preserves flexibility but costs more over the term and may leave no ownership. Revenue-share placement removes capital cost entirely, in exchange for a per-treatment or percentage fee and reduced margin. The right choice depends less on the device than on your cash position, cost of capital, confidence in utilisation, and appetite for obsolescence risk.
The Four Models
| Model | Upfront cash | Ownership | Service responsibility | Best suited to |
|---|---|---|---|---|
| Outright purchase | Full | Immediate | Owner | Strong cash position; proven, high-utilisation device |
| Equipment finance | Deposit | At end of term | Owner | Cash-preserving growth; confident utilisation |
| Operating lease | Low or none | Lessor (often option to buy) | Varies by contract | Fast technology cycles; uncertain long-term fit |
| Revenue-share placement | None | Supplier | Usually supplier | Unproven demand; testing a new service line |
Outright Purchase
Strengths: lowest total cost over the ownership period, full control over utilisation and pricing, no contractual constraints, and the asset appears on your balance sheet as collateral value.
Constraints: capital is tied up, you absorb all obsolescence and downtime risk, and the opportunity cost of that capital must be weighed against alternative uses.
Choose when: the device serves proven demand, you have cash above your operating reserve, and the model is not subject to rapid technological change.
Equipment Finance
Functionally a loan secured on the device: you take ownership at the end of the term, and payments are fixed.
Strengths: preserves working capital, predictable payments, and you still capture the residual value. Interest may be tax-deductible — confirm with your accountant, as treatment varies by jurisdiction.
Constraints: total cost exceeds purchase by the finance charge; the obligation continues regardless of utilisation; early exit may carry penalties.
Key discipline: the monthly payment must be comfortably covered by the device’s contribution margin at conservative utilisation, not projected utilisation. Financing a device whose payments only work at optimistic volumes is the most common path to a distressed clinic balance sheet.
Operating Lease
You pay to use the device over a defined term; the lessor retains ownership.
Strengths: minimal upfront cash, no obsolescence exposure if the term is short, and often an upgrade path at renewal. Payments are typically treated as an operating expense — again, confirm local treatment.
Constraints: higher total cost if you renew repeatedly; no residual value unless a purchase option is exercised; early termination is usually expensive; usage restrictions may apply.
Choose when: technology is evolving quickly, you are uncertain about long-term demand, or preserving cash matters more than minimising lifetime cost.
Revenue-Share Placement
The supplier places the device at no capital cost and is paid per treatment or as a percentage of revenue.
Strengths: zero capital outlay, supplier has a direct incentive to keep the device running, and it lets you validate demand before committing capital.
Constraints: the highest long-run cost per treatment if volumes are strong; margin compression on every case; contract terms often include minimum volume commitments, exclusivity, or consumable purchase obligations.
Read carefully for:
- Minimum monthly volume or payment — which converts “no risk” into a fixed obligation.
- Exclusivity and consumable lock-in — the real cost is often in mandatory consumable pricing.
- Service response commitments — a supplier-owned device is not automatically a well-serviced one.
- Exit and buyout terms — what does it cost to end early or convert to ownership?
- Data and marketing clauses — who owns patient and usage data?
Choose when: demand is genuinely unproven, capital is severely constrained, or you are trialling a new indication before investing.
Decision Framework
- Assess utilisation confidence. High confidence favours purchase or finance; low confidence favours lease or revenue-share.
- Assess cash position. Never deploy cash below your operating reserve, regardless of how attractive the ROI looks.
- Compare cost of capital. If the finance rate exceeds the return you can earn elsewhere in the business, purchasing is preferable.
- Assess obsolescence. Rapidly evolving technologies favour shorter commitments.
- Model total cost over your realistic ownership period, including residual value, and compare all four on the same basis.
- Stress-test the payment against a 40% utilisation shortfall. If it breaks, the structure is wrong for you.
Hybrid Approaches
Common and often sensible combinations include: financing a core device while taking a revenue-share placement on an experimental one; leasing for 24 months with a buyout option once utilisation is proven; or purchasing a proven platform outright while leasing the handpiece-dependent add-on technology.
Before signing any structure: have your accountant confirm the tax and balance-sheet treatment in your jurisdiction, and have a lawyer review termination, exclusivity and minimum-volume clauses. These are the two clauses most likely to cause regret.
Related reading
Frequently asked questions
Is leasing or buying better for aesthetic equipment?
It depends on utilisation confidence and cash position. Buying is cheapest over the long run and suits proven, high-utilisation devices. Leasing suits fast-evolving technology or uncertain demand, and revenue-share suits unproven service lines where capital risk should be avoided.
What are the hidden risks of revenue-share equipment placement?
The main risks are minimum volume commitments that convert a no-capital deal into a fixed obligation, exclusivity and mandatory consumable pricing that raise effective cost per treatment, vague service response commitments, and expensive early-exit or buyout terms.
How much deposit is typical for equipment finance?
Deposits vary widely by market, lender and clinic credit profile. The more important test is whether the monthly payment is comfortably covered by the device’s contribution margin at conservative — not projected — utilisation.
Can leased equipment be upgraded during the term?
Some operating leases include an upgrade path at renewal or mid-term, which is a key advantage where technology is evolving quickly. Confirm whether upgrades are contractual or discretionary before signing.
Does an operating lease appear on the balance sheet?
Accounting treatment for leases varies by jurisdiction and standard, and has changed materially under recent lease accounting rules. Confirm the current treatment with your accountant before relying on any off-balance-sheet assumption.
References
- Comparative framework — confirm tax, accounting and contract terms with local professional advisers.
Need parameter charts for your clinic?
SMIO supplies device-specific clinical parameter sheets, training and calibration reports.
Last updated: 2026-09-05 ｜ SMIO Professional Aesthetic Devices
